Vascular Biogenics logo

VBLT - Vascular Biogenics Share Price

$1.24 0.0  0.4%

Last Trade - 10/07/20

Micro Cap
Market Cap £46.7m
Enterprise Value £24.2m
Revenue £563k
Position in Universe 4551st / 6343
Unlock VBLT Revenue
Relative Strength (%)
1m -6.93%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 13.9 0.59 0.56 0.75 0.56
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Vascular Biogenics Ltd revenues increased 67% to $366K. Net loss increased 28% to $5.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development expenses, net increase of 44% to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.15.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


VBLT Revenue Unlock VBLT Revenue

Net Income

VBLT Net Income Unlock VBLT Revenue

Normalised EPS

VBLT Normalised EPS Unlock VBLT Revenue

PE Ratio Range

VBLT PE Ratio Range Unlock VBLT Revenue

Dividend Yield Range

VBLT Dividend Yield Range Unlock VBLT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VBLT EPS Forecasts Unlock VBLT Revenue
Profile Summary

Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 31, 2000
Public Since October 1, 2014
No. of Shareholders: 12
No. of Employees: 38
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 47,896,736
Free Float (0.0%)
Eligible for
VBLT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VBLT
Upcoming Events for VBLT
Tuesday 11th August, 2020 Estimate
Q2 2020 Vascular Biogenics Ltd Earnings Release
Thursday 12th November, 2020 Estimate
Q3 2020 Vascular Biogenics Ltd Earnings Release
Tuesday 22nd December, 2020 Estimate
Vascular Biogenics Ltd Annual Shareholders Meeting
Frequently Asked Questions for Vascular Biogenics
What is the Vascular Biogenics share price?

As of 10/07/20, shares in Vascular Biogenics are trading at $1.24, giving the company a market capitalisation of £46.7m. This share price information is delayed by 15 minutes.

How has the Vascular Biogenics share price performed this year?

Shares in Vascular Biogenics are currently trading at $1.24 and the price has moved by -9.56% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vascular Biogenics price has moved by -14.41% over the past year.

What are the analyst and broker recommendations for Vascular Biogenics?

Of the analysts with advisory recommendations for Vascular Biogenics, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vascular Biogenics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Vascular Biogenics next release its financial results?

Vascular Biogenics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Vascular Biogenics dividend yield?

Vascular Biogenics does not currently pay a dividend.

Does Vascular Biogenics pay a dividend?

Vascular Biogenics does not currently pay a dividend.

When does Vascular Biogenics next pay dividends?

Vascular Biogenics does not currently pay a dividend.

How do I buy Vascular Biogenics shares?

To buy shares in Vascular Biogenics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vascular Biogenics?

Shares in Vascular Biogenics are currently trading at $1.24, giving the company a market capitalisation of £46.7m.

Where are Vascular Biogenics shares listed? Where are Vascular Biogenics shares listed?

Here are the trading details for Vascular Biogenics:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: VBLT
What kind of share is Vascular Biogenics?

Based on an overall assessment of its quality, value and momentum, Vascular Biogenics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vascular Biogenics share price forecast 2020?

Shares in Vascular Biogenics are currently priced at $1.24. At that level they are trading at 0.213% discount to the analyst consensus target price of 0.00.

Analysts covering Vascular Biogenics currently have a consensus Earnings Per Share (EPS) forecast of -0.542 for the next financial year.

How can I tell whether the Vascular Biogenics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vascular Biogenics. Over the past six months, the relative strength of its shares against the market has been -5.49%. At the current price of $1.24, shares in Vascular Biogenics are trading at -4.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vascular Biogenics PE Ratio?

We were not able to find PE ratio data for Vascular Biogenics.

Who are the key directors of Vascular Biogenics?

Vascular Biogenics's management team is headed by:

Bennett Shapiro - CHM
Dror Harats - CEO
Amos Ron - CFO
Eyal Breitbart - VOP
Naamit Sher - VPR
Yael Cohen - VPR
Erez Feige - VOP
Ruth Alon - NED
Ayelet Horn - GCN
Ron Cohen - NED
Jecheskiel Gonczarowski - NID
Ruth Arnon - NID
Philip Serlin - NID
Who are the major shareholders of Vascular Biogenics?

Here are the top five shareholders of Vascular Biogenics based on the size of their shareholding:

Aurum Ventures M.K.I. Venture Capital
Percentage owned: 8.98% (4.30m shares)
Thai Lee Family Trust Corporation
Percentage owned: 8.55% (4.10m shares)
Lee (Thai) Individual Investor
Percentage owned: 8.27% (3.96m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 4.59% (2.20m shares)
Harats (Dror) Individual Investor
Percentage owned: 3.61% (1.73m shares)
Similar to VBLT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.